New Horizons Forum
- email
Thanks for emailing that article!
Join us for the 2nd Annual New Horizons Forum: speeding the development of new therapies and diagnostics for glaucoma patients. Register online.
February 1, 2013 — The Palace Hotel, San Francisco, California
The centerpiece of Glaucoma 360, the New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
Launched in early 2012 by Glaucoma Research Foundation, this catalyst meeting is designed to bring the essential components together in order to speed the translation of new ideas into clinical practice.
What others are saying about the New Horizons Forum:
“The meeting provided an opportunity for a good deal of ‘cross fertilization.’ As an immediate and direct result we are now meeting with a major company for potential delivery of one compound and a start-up company for delivery of a novel compound. I can only imagine how much effort it takes to create such a unique meeting and then to execute it flawlessly.”
- Robert Thompson, CEO, Amorphex Therapeutics
“The first annual New Horizons Forum was, by any measures, a tremendous success.”
- Larry Haimovitch, Medical Device Daily
“This is the glaucoma meeting to attend.”
- George A. Cioffi, MD, Chairman, Department of Ophthalmology, Columbia University College of Physicians and Surgeons
Who should attend:
- Early-stage company CEOs and executives
- Business Development and other representatives from companies that offer pharmaceuticals, devices, drug delivery, and IOP monitoring for glaucoma patients
- Key Opinion Leaders and Leading Ophthalmologists
- Industry Executives
- Venture Capitalists
- Representatives from Clinical Research Organizations
- Scientific innovators
Leadership
Founder and Co-Chair
Adrienne Graves, PhD
Consultant Pharmaceutical Industry
and former President & CEO Santen, Inc.
Founder and Co-Chair
Andrew G. Iwach, MD
Executive Director
Glaucoma Center of San Francisco
New Horizons 2013 Advisory Board
Stuart B. Abelson, MBA
President, Chief Executive Officer, Ora, Inc.
Anthony P. Adamis, MD
Vice President and Global Head of Ophthalmology, Genentech, Inc.
Paul Chaney
President and CEO, PanOptica, Inc.
George A. Cioffi, MD
Chairman, Department of Ophthalmology
Columbia University College of Physicians and Surgeons
Alan Crandall, MD
Director of Glaucoma and Cataract, Senior Vice Chairman of Ophthalmology & Visual Sciences
John A. Moran Eye Center, University of Utah
Emmett Cunningham, Jr., MD, PhD, MPH
Partner, Clarus Ventures
Eugene de Juan, Jr., MD
Founder and Vice-Chairman, ForSight Labs
David Epstein, MD, MMM
Joseph A.C. Wadsworth Clinical Professor and Chairman of the Department of Ophthalmology, Duke Eye Center
John W. Grunden, PharmD
Regional Director of Medical Affairs for Ophthalmology (USA/EU/Can)
Merck & Co., Inc.
David Guyer, MD
Partner, SV Life Sciences Advisers, LLC
Eve Higginbotham, SM, MD
Visiting Scholar in Health Equity at the Association of American Medical Colleges in Washington D.C.
H. Dunbar Hoskins, Jr., MD
Co-Founder and Director of Glaucoma Research Foundation, and
Former Executive Vice President, American Academy of Ophthalmology
Wende Hutton
General Partner, Canaan Partners
Ralf Kuschnereit, PhD
President and Chief Executive Officer, Carl Zeiss Meditec Inc.
Eliot Lazar, MD
President, elCon Medical
Paul Lee, MD, JD
F. Bruce Fralick Professor and Chair, Department of Ophthalmology and Visual Sciences and Director, W.K. Kellogg Eye Center, University of Michigan
Richard Lindstrom, MD
Founder, Minnesota Eye Consultants, PA
William J. Link, PhD
Managing Director, Versant Ventures
Sabri Markabi, MD
Sr. Vice President, Research & Development, and Chief Medical Officer
Alcon Laboratories, Inc.
James Mazzo
President and CEO, Abbot Medical Optics
J. Casey McGlynn, JD
Partner, Wilson Sonsini Goodrich & Rosati
Gary D. Novack, PhD
President, PharmaLogic Development, Inc.
David E. I. Pyott
Chairman of the Board, President and Chief Executive Officer
Allergen, Inc.
Kuldev Singh, MD, MPH
Professor of Ophthalmology and Director, Glaucoma Service
Stanford University Medical Center
Ellen Strahlman, MD, MHSc
Chief Medical Officer, GlaxoSmithKline
Ruth D. Williams, MD
President, American Academy of Ophthalmology
President, Wheaton Eye Clinic
M. Roy Wilson, MD
Deputy Director, Strategic Scientific Planning and Program Coordination National Institute on Minority Health and Health Disparities
National Institutes of Health
Program
Download the 2012 program booklet (PDF 1.5 MB)
Overview of 2012 program:
Presentations by Early-Stage Glaucoma Companies
AcuMEMS, Inc., Aerie Pharmaceuticals, Altheos Inc., Amakem NV, Amorphex Therapeutics LLC, Compact Imaging, Inc., Glaukos, Implandata Ophthalmic Products, iScience, Isis Pharmaceuticals, Inc., NeoMedix, Optovue, pSivida, Transcend Medical, Inc.
Glaucoma Venture Capital panel
Speakers
Wiley A. Chambers, MD
George A. Cioffi, MD
Malvina B. Eydelman, MD
H. Dunbar Hoskins, Jr., MD
James Mazzo
Martin B. Wax, MD
Panel Discussions
* Glaucoma Treatment Devices
* Glaucoma Pharmaceuticals
* Glaucoma Drug and Device Approval Process
* Investing in Glaucoma (Venture Capital)
2013 Program Schedule
The second annual New Horizons Forum, a full-day program, will take place February 1, 2013 at The Palace Hotel in downtown San Francisco. Click here to view the Agenda.
7:00 AM - Registration, Breakfast, and Exhibits
7:30 AM to 5:30 PM - Program
5:30 PM to 7:00 PM - Reception
New Horizons Exhibit Hall — 7:00 AM to 7:00 PM
Proceeds from the New Horizons Forum benefit the Glaucoma Research Foundation for use in our grant-making and other operational priorities.
Sponsorship Opportunities
To review sponsorship opportunities, please download an overview of New Horizons Forum sponsorship and marketing opportunities (PDF) or contact Aileen Trieu at Glaucoma Research Foundation at (415) 986-3162 for more information.
Learn More and Register
Learn more about the Glaucoma 360 New Horizons Forum.
Register online for the New Horizons Forum.
For more information, please email Aileen Trieu at Glaucoma Research Foundation, or call (415) 986-3162.
Last reviewed on December 10, 2012
